A novel TLR7 agonist reverses NK cell anergy and cures RMA-S lymphoma-bearing mice

References

• Uematsu S, Akira S. Toll-like receptors and innate immunity. J Mol Med (Berl) 2006; 84:712-25; PMID:16924467; http://dx.doi.org/10.1007/s00109-006-0084-y
   PubMed Web of Science ®Google Scholar
• Heil F, Hemmi H, Hochrein H, Ampenberger F, Kirschning C, Akira S, Lipford G, Wagner H, Bauer S. Species-specific recognition of single-stranded RNA via toll-like receptor 7 and 8. Science 2004; 303:1526-9; PMID:14976262; http://dx.doi.org/10.1126/science.1093620
   PubMed Web of Science ®Google Scholar
• Hornung V, Guenthner-Biller M, Bourquin C, Ablasser A, Schlee M, Uematsu S, Noronha A, Manoharan M, Akira S, de Fougerolles A et al. Sequence-specific potent induction of IFN-alpha by short interfering RNA in plasmacytoid dendritic cells through TLR7. Nat Med 2005; 11:263-70; PMID:15723075; http://dx.doi.org/10.1038/nm1191
   PubMed Web of Science ®Google Scholar
• Hemmi H, Kaisho T, Takeuchi O, Sato S, Sanjo H, Hoshino K, Horiuchi T, Tomizawa H, Takeda K, Akira S. Small anti-viral compounds activate immune cells via the TLR7 MyD88-dependent signaling pathway. Nat Immunol 2002; 3:196-200; PMID:11812998; http://dx.doi.org/10.1038/ni758
   PubMed Web of Science ®Google Scholar
• Bourquin C, L Schmidt, AL Lanz, B Storch, C Wurzenberger, Anz D, Sandholzer N, Mocikat R, Berger M, Poeck H et al. Immunostimulatory RNA oligonucleotides induce an effective antitumoral NK cell response through the TLR7. J Immunol 2009; 183:6078-86; PMID:19890064; http://dx.doi.org/10.4049/jimmunol.0901594
   PubMed Web of Science ®Google Scholar
• Gilliet M, Cao W, Liu YJ. Plasmacytoid dendritic cells: sensing nucleic acids in viral infection and autoimmune diseases. Nat Rev Immunol 2008; 8:594-606; PMID:18641647; http://dx.doi.org/10.1038/nri2358
   PubMed Web of Science ®Google Scholar
• Schreiber RD, Old LJ, Smyth MJ. Cancer immunoediting: integrating immunity's roles in cancer suppression and promotion. Science 2011; 331:1565-70; PMID:21436444; http://dx.doi.org/10.1126/science.1203486
   PubMed Web of Science ®Google Scholar
• Kobold S, Wiedemann G, Rothenfusser S, Endres S. Modes of action of TLR7 agonists in cancer therapy. Immunotherapy 2014; 6:1085-95; PMID:25428647; http://dx.doi.org/10.2217/imt.14.75
   PubMed Web of Science ®Google Scholar
• Vacchelli E, Eggermont A, Sautes-Fridman C, Galon J, Zitvogel L, Kroemer G, Galluzzi L. Trial Watch: Toll-like receptor agonists for cancer therapy. Oncoimmunology 2013; 2:e25238; PMID:24083080; http://dx.doi.org/10.4161/onci.25238
   PubMed Web of Science ®Google Scholar
• Adams S, Kozhaya L, Martiniuk F, Meng TC, Chiriboga L, Liebes L, Hochman T, Shuman N, Axelrod D, Speyer J et al. Topical TLR7 agonist imiquimod can induce immune-mediated rejection of skin metastases in patients with breast cancer. Clin Cancer Res 2012; 18:6748-57; PMID:22767669; http://dx.doi.org/10.1158/1078-0432.CCR-12-1149
   PubMed Web of Science ®Google Scholar
• Naylor MF, Crowson N, Kuwahara R, Teague K, Garcia C, Mackinnis C, Haque R, Odom C, Jankey C, Cornelison RL et al. Treatment of lentigo maligna with topical imiquimod. Br J Dermatol 2003; 149(Suppl 66):66-70; PMID:14616356; http://dx.doi.org/10.1046/j.0366-077X.2003.05637.x
   PubMed Web of Science ®Google Scholar
• Schulze HJ, Cribier B, Requena L, Reifenberger J, Ferrandiz C, Garcia Diez A, Tebbs V, McRae S. Imiquimod 5% cream for the treatment of superficial basal cell carcinoma: results from a randomized vehicle-controlled phase III study in Europe. Br J Dermatol 2005; 152:939-47; PMID:15888150; http://dx.doi.org/10.1111/j.1365-2133.2005.06486.x
   PubMed Web of Science ®Google Scholar
• Holldack J. Toll-like receptors as therapeutic targets for cancer. Drug Discov Today 2014; 19:379-82; PMID:24012797; http://dx.doi.org/10.1016/j.drudis.2013.08.020
   PubMed Web of Science ®Google Scholar
• Lanier LL. NK cell recognition. Annu Rev Immunol 2005; 23:225-274; PMID:15771571; http://dx.doi.org/10.1146/annurev.immunol.23.021704.115526
   PubMed Web of Science ®Google Scholar
• Moretta L, Pietra G, Montaldo E, Vacca P, Pende D, Falco M, Del Zotto G, Locatelli F, Moretta A, Mingari MC. Human NK cells: from surface receptors to the therapy of leukemias and solid tumors. Front Immunol 2014; 5:87; PMID:24639677; http://dx.doi.org/10.3389/fimmu.2014.00087
   PubMed Web of Science ®Google Scholar
• Long EO, Kim HS, Liu D, Peterson ME, Rajagopalan S. Controlling natural killer cell responses: integration of signals for activation and inhibition. Annu Rev Immunol 2013; 31:227-58; PMID:23516982; http://dx.doi.org/10.1146/annurev-immunol-020711-075005
   PubMed Web of Science ®Google Scholar
• Da Silva IP, Gallois A, Jimenez-Baranda S, Khan S, Anderson AC, Kuchroo VK, Osman I, Bhardwaj N. Reversal of NK-cell exhaustion in advanced melanoma by Tim-3 blockade. Cancer Immunol Res 2014; 2:410-22; PMID:24795354; http://dx.doi.org/10.1158/2326-6066.CIR-13-0171
   PubMed Web of Science ®Google Scholar
• Gill S, Vasey AE, De Souza A, Baker J, Smith AT, Kohrt HE, Florek M, Gibbs KD Jr, Tate K, Ritchie DS et al. Rapid development of exhaustion and down-regulation of eomesodermin limit the antitumor activity of adoptively transferred murine natural killer cells. Blood 2012; 119:5758-68; PMID:22544698; http://dx.doi.org/10.1182/blood-2012-03-415364
   PubMed Web of Science ®Google Scholar
• Smyth MJ, Cretney E, Kershaw MH, Hayakawa Y. Cytokines in cancer immunity and immunotherapy. Immunol Rev 2004; 202:275-293; PMID:15546400; http://dx.doi.org/10.1111/j.0105-2896.2004.00199.x
   PubMed Web of Science ®Google Scholar
• Krause SW, Gastpar R, Andreesen R, Gross C, Ullrich H, Thonigs G, Pfister K, Multhoff G. Treatment of colon and lung cancer patients with ex vivo heat shock protein 70-peptide-activated, autologous natural killer cells: a clinical phase i trial. Clin Cancer Res 2004; 10:3699-707; PMID:15173076; http://dx.doi.org/10.1158/1078-0432.CCR-03-0683
   PubMed Web of Science ®Google Scholar
• Miller JS, Tessmer-Tuck J, Pierson BA, Weisdorf D, McGlave P, Blazar BR, Katsanis E, Verfaillie C, Lebkowski J, Radford J Jr et al. Low dose subcutaneous interleukin-2 after autologous transplantation generates sustained in vivo natural killer cell activity. Biol Blood Marrow Transplant 1997; 3:34-44; PMID:9209739
   PubMedGoogle Scholar
• Rosenberg SA, Mule JJ, Spiess PJ, Reichert CM, Schwarz SL. Regression of established pulmonary metastases and subcutaneous tumor mediated by the systemic administration of high-dose recombinant interleukin 2. J Exp Med 1985; 161:1169-88; PMID:3886826; http://dx.doi.org/10.1084/jem.161.5.1169
   PubMed Web of Science ®Google Scholar
• Tarek N, Le Luduec JB, Gallagher MM, Zheng J, Venstrom JM, Chamberlain E, Modak S, Heller G, Dupont B, Cheung NK et al. Unlicensed NK cells target neuroblastoma following anti-GD2 antibody treatment. J Clin Invest 2012; 122:3260-70; PMID:22863621; http://dx.doi.org/10.1172/JCI62749
   PubMed Web of Science ®Google Scholar
• Ma C, Armstrong AW. Severe adverse events from the treatment of advanced melanoma: a systematic review of severe side effects associated with ipilimumab, vemurafenib, interferon alfa-2b, dacarbazine and interleukin-2. J Dermatolog Treat 2014; 25:401-8; PMID:23763243; http://dx.doi.org/10.3109/09546634.2013.813897
   PubMed Web of Science ®Google Scholar
• Geller MA, Cooley S, Judson PL, Ghebre R, Carson LF, Argenta PA, Jonson AL, Panoskaltsis-Mortari A, Curtsinger J, McKenna D et al. A phase II study of allogeneic natural killer cell therapy to treat patients with recurrent ovarian and breast cancer. Cytotherapy 2011; 13:98-107; PMID:20849361; http://dx.doi.org/10.3109/14653249.2010.515582
   PubMed Web of Science ®Google Scholar
• Parkhurst MR, Riley JP, Dudley ME, Rosenberg SA. Adoptive transfer of autologous natural killer cells leads to high levels of circulating natural killer cells but does not mediate tumor regression. Clin Cancer Res 2011; 17:6287-97; PMID:21844012; http://dx.doi.org/10.1158/1078-0432.CCR-11-1347
   PubMed Web of Science ®Google Scholar
• Hamm S, Rath S, Michel S, Baumgartner R. Cancer immunotherapeutic potential of novel small molecule TLR7 and TLR8 agonists. J Immunotoxicol 2009; 6:257-65; PMID:19848448; http://dx.doi.org/10.3109/15476910903286733
   PubMed Web of Science ®Google Scholar
• Lamphier M, Zheng W, Latz E, Spyvee M, Hansen H, Rose J, Genest M, Yang H, Shaffer C, Zhao Y et al. Novel small molecule inhibitors of TLR7 and TLR9: mechanism of action and efficacy in vivo. Mol Pharmacol 2014; 85:429-40; PMID:24342772; http://dx.doi.org/10.1124/mol.113.089821
   PubMed Web of Science ®Google Scholar
• Dummer R, Hauschild A, Becker JC, Grob JJ, Schadendorf D, Tebbs V, Skalsky J, Kaehler KC, Moosbauer S, Clark R et al. An exploratory study of systemic administration of the toll-like receptor-7 agonist 852A in patients with refractory metastatic melanoma. Clin Cancer Res 2008; 14:856-64; PMID:18245549; http://dx.doi.org/10.1158/1078-0432.CCR-07-1938
   PubMed Web of Science ®Google Scholar
• Dovedi SJ, Melis MH, Wilkinson RW, Adlard AL, Stratford IJ, Honeychurch J, Illidge TM. Systemic delivery of a TLR7 agonist in combination with radiation primes durable antitumor immune responses in mouse models of lymphoma. Blood 2013; 121:251-9; PMID:23086756; http://dx.doi.org/10.1182/blood-2012-05-432393
   PubMed Web of Science ®Google Scholar
• Ignatz-Hoover JJ, Wang H, Moreton SA, Chakrabarti A, Agarwal MK, Sun K, Gupta K, Wald DN. The role of TLR8 signaling in acute myeloid leukemia differentiation. Leukemia 2015; 29:918-26; PMID:25283842; http://dx.doi.org/10.1038/leu.2014.293
   PubMed Web of Science ®Google Scholar
• Karre K, Ljunggren HG, Piontek G, Kiessling R. Selective rejection of H-2-deficient lymphoma variants suggests alternative immune defence strategy. Nature 1986; 319:675-8; PMID:3951539; http://dx.doi.org/10.1038/319675a0
   PubMed Web of Science ®Google Scholar
• Kanneganti TD, Ozoren N, Body-Malapel M, Amer A, Park JH, Franchi L, Whitfield J, Barchet W, Colonna M, Vandenabeele P et al. Bacterial RNA and small antiviral compounds activate caspase-1 through cryopyrin/Nalp3. Nature 2006; 440:233-6; PMID:16407888; http://dx.doi.org/10.1038/nature04517
   PubMed Web of Science ®Google Scholar
• Agarwala SS, Kirkwood JM, Bryant J. Phase 1, randomized, double-blind trial of 7-allyl-8-oxoguanosine (loxoribine) in advanced cancer. Cytokines Cell Mol Ther 2000; 6:171-6; PMID:11565955; http://dx.doi.org/10.1080/mccm.6.4.171.176
   PubMed Web of Science ®Google Scholar
• Falke J, Lammers RJ, Arentsen HC, Ravic M, Pozzi R, Cornel EB, Vergunst H, de Reijke TM, Witjes JA. Results of a phase 1 dose escalation study of intravesical TMX-101 in patients with nonmuscle invasive bladder cancer. J Urol 2013; 189:2077-82; PMID:23206424; http://dx.doi.org/10.1016/j.juro.2012.11.150
   PubMed Web of Science ®Google Scholar
• Weigel BJ, Cooley S, DeFor T, Weisdorf DJ, Panoskaltsis-Mortari A, Chen W, Blazar BR, Miller JS. Prolonged subcutaneous administration of 852A, a novel systemic toll-like receptor 7 agonist, to activate innate immune responses in patients with advanced hematologic malignancies. Am J Hematol 2012; 87:953-6; PMID:22718533; http://dx.doi.org/10.1002/ajh.23280
   PubMed Web of Science ®Google Scholar
• Inglefield JR, Dumitru CD, Alkan SS, Gibson SJ, Lipson KE, Tomai MA, Larson CJ, Vasilakos JP. TLR7 agonist 852A inhibition of tumor cell proliferation is dependent on plasmacytoid dendritic cells and type I IFN. J Interferon Cytokine Res 2008; 28:253-63; PMID:18439103; http://dx.doi.org/10.1089/jir.2007.0097
   PubMed Web of Science ®Google Scholar
• Christian LM, Porter K, Karlsson E, Schultz-Cherry S. Proinflammatory cytokine responses correspond with subjective side effects after influenza virus vaccination. Vaccine 2015; 33(29):3360-6; PMID:26027906; http://dx.doi.org/10.1016/j.vaccine.2015.05.008
   PubMed Web of Science ®Google Scholar
• Harrison LI, Astry C, Kumar S, Yunis C. Pharmacokinetics of 852A, an imidazoquinoline Toll-like receptor 7-specific agonist, following intravenous, subcutaneous, and oral administrations in humans. J Clin Pharmacol 2007; 47:962-9; PMID:17660481; http://dx.doi.org/10.1177/0091270007303766
   PubMed Web of Science ®Google Scholar
• Davies A, Merli F, Mihaljevic B, Siritanaratkul N, Solal-Celigny P, Barrett M, Berge C, Bittner B, Boehnke A, McIntyre C et al. Pharmacokinetics and safety of subcutaneous rituximab in follicular lymphoma (SABRINA): stage 1 analysis of a randomised phase 3 study. Lancet Oncol 2014; 15:343-52; PMID:24521993; http://dx.doi.org/10.1016/S1470-2045(14)70005-1
   PubMed Web of Science ®Google Scholar
• Gorden KB, Gorski KS, Gibson SJ, Kedl RM, Kieper WC, Qiu X, Tomai MA, Alkan SS, Vasilakos JP. Synthetic TLR agonists reveal functional differences between human TLR7 and TLR8. J Immunol 2005; 174:1259-68; PMID:15661881; http://dx.doi.org/10.4049/jimmunol.174.3.1259
   PubMed Web of Science ®Google Scholar
• Hart OM, Athie-Morales V, O'Connor GM, Gardiner CM. TLR7/8-mediated activation of human NK cells results in accessory cell-dependent IFN-gamma production. J Immunol 2005; 175:1636-42; PMID:16034103; http://dx.doi.org/10.4049/jimmunol.175.3.1636
   PubMed Web of Science ®Google Scholar
• Liu J, Xu C, Hsu LC, Luo Y, Xiang R, Chuang TH. A five-amino-acid motif in the undefined region of the TLR8 ectodomain is required for species-specific ligand recognition. Mol Immunol 2010; 47:1083-90; PMID:20004021; http://dx.doi.org/10.1016/j.molimm.2009.11.003
   PubMed Web of Science ®Google Scholar
• Gorden KK, Qiu XX, Binsfeld CC, Vasilakos JP, Alkan SS. Cutting edge: activation of murine TLR8 by a combination of imidazoquinoline immune response modifiers and polyT oligodeoxynucleotides. J Immunol 2006; 177:6584-87; PMID:17082568; http://dx.doi.org/10.4049/jimmunol.177.10.6584
   PubMed Web of Science ®Google Scholar
• Belanger S, Tu MM, Rahim MM, Mahmoud AB, Patel R, Tai LH, Troke AD, Wilhelm BT, Landry JR, Zhu Q et al. Impaired natural killer cell self-education and “missing-self” responses in Ly49-deficient mice. Blood 2012; 120:592-602; PMID:22661698; http://dx.doi.org/10.1182/blood-2012-02-408732
   PubMed Web of Science ®Google Scholar
• Chan CJ, Martinet L, Gilfillan S, Souza-Fonseca-Guimaraes F, Chow MT, Town L, Ritchie DS, Colonna M, Andrews DM, Smyth MJ. The receptors CD96 and CD226 oppose each other in the regulation of natural killer cell functions. Nat Immunol 2014; 15:431-8; PMID:24658051; http://dx.doi.org/10.1038/ni.2850
   PubMed Web of Science ®Google Scholar
• Hayakawa Y, Smyth MJ. NKG2D and cytotoxic effector function in tumor immune surveillance. Semin Immunol 2006; 18:176-85; PMID:16675266; http://dx.doi.org/10.1016/j.smim.2006.03.005
   PubMed Web of Science ®Google Scholar
• Bryceson YT, March ME, Ljunggren HG, Long EO. Activation, coactivation, and costimulation of resting human natural killer cells. Immunol Rev 2006; 214:73-91; PMID:17100877; http://dx.doi.org/10.1111/j.1600-065X.2006.00457.x
   PubMed Web of Science ®Google Scholar
• Bourquin C, Hotz C, Noerenberg D, Voelkl A, Heidegger S, Roetzer LC, Storch B, Sandholzer N, Wurzenberger C, Anz D et al. Systemic cancer therapy with a small molecule agonist of toll-like receptor 7 can be improved by circumventing TLR tolerance. Cancer Res 2011; 71:5123-33; PMID:21697281; http://dx.doi.org/10.1158/0008-5472.CAN-10-3903
   PubMed Web of Science ®Google Scholar
• Ogawa T, Tsuji-Kawahara S, Yuasa T, Kinoshita S, Chikaishi T, Takamura S, Matsumura H, Seya T, Saga T, Miyazawa M. Natural killer cells recognize friend retrovirus-infected erythroid progenitor cells through NKG2D-RAE-1 interactions In Vivo. J Virol 2011; 85:5423-35; PMID:21411527; http://dx.doi.org/10.1128/JVI.02146-10
   PubMed Web of Science ®Google Scholar
• Ardolino M, Azimi CS, Iannello A, Trevino TN, Horan L, Zhang L, Deng W, Ring AM, Fischer S, Garcia KC et al. Cytokine therapy reverses NK cell anergy in MHC-deficient tumors. J Clin Invest 2014; 124:4781-94; PMID:25329698; http://dx.doi.org/10.1172/JCI74337
   PubMed Web of Science ®Google Scholar